Traders Sell Shares of Eli Lilly and Co. (LLY) on Strength (LLY)
Traders sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading hours on Friday. $32.89 million flowed into the stock on the tick-up and $50.67 million flowed out of the stock on the tick-down, for a money net flow of $17.78 million out of the stock. Of all stocks tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.23 for the day and closed at $78.24
A number of equities analysts recently commented on LLY shares. TheStreet upgraded Eli Lilly and from a “hold” rating to a “buy” rating in a research note on Friday, May 27th. Credit Suisse Group AG reiterated a “buy” rating on shares of Eli Lilly and in a research note on Thursday, May 26th. Jefferies Group reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Friday, May 13th. Argus lifted their price target on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Finally, Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research note on Friday, July 29th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Buy” and a consensus target price of $96.58.
The firm has a market cap of $82.75 billion and a PE ratio of 33.72. The stock has a 50-day moving average of $80.68 and a 200-day moving average of $76.10.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.86. During the same period in the previous year, the firm earned $0.90 EPS. The business earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. The business’s revenue was up 8.6% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Co. will post $3.59 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be paid a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, August 11th. This represents a $2.04 annualized dividend and a yield of 2.61%.
In other news, Director Jackson P. Tai acquired 2,560 shares of the firm’s stock in a transaction on Friday, August 12th. The shares were purchased at an average cost of $80.42 per share, with a total value of $205,875.20. Following the completion of the purchase, the director now owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Melissa S. Barnes sold 992 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $73.77, for a total transaction of $73,179.84. Following the sale, the senior vice president now directly owns 10,710 shares in the company, valued at $790,076.70. The disclosure for this sale can be found here.
A number of hedge funds have recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC boosted its stake in shares of Eli Lilly and by 1.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 20,579 shares of the company’s stock valued at $1,734,000 after buying an additional 239 shares in the last quarter. Airain ltd purchased a new stake in shares of Eli Lilly and during the fourth quarter valued at $1,766,000. Stephens Inc. AR boosted its stake in shares of Eli Lilly and by 10.7% in the fourth quarter. Stephens Inc. AR now owns 35,447 shares of the company’s stock valued at $2,987,000 after buying an additional 3,426 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter valued at $4,539,000. Finally, King Luther Capital Management Corp boosted its stake in shares of Eli Lilly and by 1.4% in the fourth quarter. King Luther Capital Management Corp now owns 186,246 shares of the company’s stock valued at $15,693,000 after buying an additional 2,562 shares in the last quarter.
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.